HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) and maintains a $5 price target.
March 15, 2024 | 10:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Akebia Therapeutics with a $5 price target.
The reiteration of a Buy rating and maintenance of a $5 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence among investors and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100